Double-blind placebo controlled trial of the anxiolytic effects of a standardized Echinacea extract
Corresponding Author
József Haller
Institute of Experimental Medicine, Budapest, Hungary
University of Public Service, Budapest, Hungary
Correspondence
Jozsef Haller
Institute of Experimental Medicine
1450 Budapest, P.O. Box 67
Hungary
Phone: +36 1210 9406
Email: [email protected]
Search for more papers by this authorCorresponding Author
József Haller
Institute of Experimental Medicine, Budapest, Hungary
University of Public Service, Budapest, Hungary
Correspondence
Jozsef Haller
Institute of Experimental Medicine
1450 Budapest, P.O. Box 67
Hungary
Phone: +36 1210 9406
Email: [email protected]
Search for more papers by this authorAbstract
Earlier studies suggested that specific Echinacea preparations might decrease anxiety. To further study the issue, we performed a double blind, placebo controlled trial with a standardized Echinacea angustifolia root extract. Participants were volunteers scoring above 45 points on the state or on the trait subscale of the State Trait Anxiety Inventory (STAI). They were treated with 40 mg Echinacea or with placebo tablets twice daily for 7 days followed by a 3 week-long washout period. Participants were also administered the Beck Depression Inventory (BDI) and the Perceived Stress Scale (PSS). In the Echinacea group, state anxiety scores decreased by approximately 11 points by the end of the treatment period, whereas the decrease was around 3-points in the placebo group (p< 0.01). The effect maintained over the washout period. The difference from placebo was significant from the 7th day of treatment throughout. Changes were less robust with trait anxiety scores, but the preparation performed better than placebo in patients with high baseline anxiety. Neither BDI nor PSS scores were affected by the treatments. Adverse effects were rare and mild, and all were observed in the placebo group. These findings suggest that particular Echinacea preparations have significant beneficial effects on anxiety in humans.
REFERENCES
- Agoston, G., & Szili, I. (2001). Diagnosztikus kérdőívek és tünetbecslő skálák. In J. Füredi, A. Németh, & P. Tariska (Eds.), A pszichiátria magyar kézikönyve (pp. 176–183). Budapest: Medicina.
- Bakker, A., van Dyck, R., Spinhoven, P., & van Balkom, A. J. (1999). Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psych, 60, 831–838.
- Barnes, J., Anderson, L. A., Gibbons, S., & Phillipson, J. D. (2005). Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol, 57, 929–954.
- Batelaan, N. M., Smit, F., de Graaf, R., van Balkom, A. J., Vollebergh, W. A., & Beekman, A. T. (2010). Identifying target groups for the prevention of anxiety disorders in the general population. Acta Psychiatr Scand, 122, 56–65.
- Bauer, R., & Remiger, P. (1989). TLC and HPLC Analysis of Alkamides in Echinacea Drugs. Planta Med, 55, 367–371.
- Beck, A. T., Ward, C. H., Mendelsohn, M., & Mock, J. (1961). An inventory for measuring depression. Arch Gen Psychiat, 4, 561–571.
- Birt, D. F., Widrlechner, M. P., Lalone, C. A., et al. (2008). Echinacea in infection. Am J Clin Nutr, 87, 488S–492S.
- Borchers, A. T., Keen, C. L., Stern, J. S., & Gershwin, M. E. (2000). Inflammation and Native American medicine: the role of botanicals. Am J Clin Nutr, 72, 339–347.
- Burgess, P. M., Pirkis, J. E., Slade, T. N., Johnston, A. K., Meadows, G. N., & Gunn, J. M. (2009). Service use for mental health problems: findings from the 2007 National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry, 43, 615–623.
- Bystritsky, A., Kerwin, L., Niv, N., Natoli, J. L., Abrahami, N., Klap, R., … Young, A. S. (2010). Clinical and subthreshold panic disorder. Depress Anxiety, 27, 381–389.
- Cohen, S., Kamarck, T., & Mermelstein, R. (1983). A global measure of perceived stress. J Health Soc Behav, 24, 385–396.
- Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002). The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci, 16, 1395–1398.
- Haller, J., Freund, T. F., Pelczer, K. G., Füredi, J., Krecsak, L., & Zámbori, J. (2013). The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers. Phytother Res, 27, 54–61.
- Haller, J., Hohmann, J., & Freund, T. F. (2010). The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide. Phytother Res, 24, 1605–1613.
- Hohmann, J., Rédei, D., Forgo, P., Szabó, P., Freund, T. F., Haller, J., … Benyhe, S. (2011). Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors. Phytochemistry, 72, 1848–1853.
- Izzo, A. A., & Ernst, E. (2001). Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs, 61, 2163–2175.
- Karsten, J., Penninx, B. W., Verboom, C. E., Nolen, W. A., & Hartman, C. A. (2013). Course and risk factors of functional impairment in subthreshold depression and anxiety. Depress Anxiety, 30, 386–394.
- Kenny, D. A. (1987). Statistics for the social and behavioral sciences. Boston: Little. Brown.
- Kraus, G. A., Bae, J., Wu, L., & Wurtele, E. (2006). Synthesis and natural distribution of anti-inflammatory alkamides from Echinacea. Molecules, 11, 758–767.
- Manayi, A., Vazirian, M., & Saeidnia, S. (2015). Echinacea purpurea: Pharmacology, phytochemistry and analysis methods. Pharmacogn Rev, 9, 63–72.
- Nauta, M. H., Festen, H., Reichart, C. G., Nolen, W. A., Stant, A. D., Bockting, C. L., … de Vries, S. O. (2012). Preventing mood and anxiety disorders in youth: a multi-centre RCT in the high risk offspring of depressed and anxious patients. BMC Psychiatry, 12, 31.
- Parsons, J. L., Cameron, S. I., Harris, C. S., & Smith, M. L. (2018). Echinacea biotechnology: advances, commercialization and future considerations. Pharm Biol, 56, 485–494.
- Pertwee, R. G. (2012). Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci, 367, 3353–3363.
- Piomelli, D., Tarzia, G., Duranti, A., et al. (2006). Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev, 12, 21–38.
- Rehman, J., Dillow, J. M., Carter, S. M., Chou, J., Le, B., & Maisel, A. S. (1999). Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunol Lett, 68, 391–395.
- Sarris, J., McIntyre, E., & Camfield, D. A. (2013). Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs, 27, 301–419.
- Siddall, P. J., Cousins, M. J., Otte, A., Griesing, T., Chambers, R., & Murphy, T. K. (2006). Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology, 67, 1792–1800.
- Sipos, K., & Sipos, M. (1978). The development and validation of the Hungarian form of the STAI. In C. D. Spielberger, & D. Guerrero (Eds.), Cross-Cultural Anxiety ( 2nd ed.) (pp. 51–61). Washington: Hemisphere Publishing.
- Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970). Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologist Press.
10.1037/013734 Google Scholar
- Stauder, A., & Konkoly, T. B. (2006). Characteristics of the Hungarian version of the Perceived Stress Scale (PSS). Mentalhigienes Pszichoszomatika, 7, 203–216.
10.1556/Mental.7.2006.3.4 Google Scholar
- Tesch, B. J. (2003). Herbs commonly used by women: an evidence based review. Am J Obstet Gynecol, 188, S44–S55.
- Thewissen, V., Bentall, R. P., Oorschot, M., Campo, J., van Lierop, T., van Os, J., & Myin-Germeys, I. (2011). Emotions, self-esteem, and paranoid episodes: an experience sampling study. Br J Clin Psychol, 50, 178–195.
- Unick, G. J., Snowden, L., & Hastings, J. (2009). Heterogeneity in comorbidity between major depressive disorder and generalized anxiety disorder and its clinical consequences. J Nerv Ment Dis, 197, 215–224.
- Van't Veer-Tazelaar, P., Smit, F., van Hout, H., van Oppen, P., van der Horst, H., Beekman, A., & van Marwijk, H. (2010). Cost-effectiveness of a stepped care intervention to prevent depression and anxiety in late life: randomised trial. Br J Psychiatry, 196, 319–325.
- Woelkart, K., Xu, W., Pei, Y., Makriyannis, A., Picone, R. P., & Bauer, R. (2005). The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med, 71, 701–705.
- Wu, L., Dixon, P. M., Nikolau, B. J., Kraus, G. A., Widrlechner, M. P., & Wurtele, E. S. (2009). Metabolic profiling of Echinacea genotypes and a test of alternative taxonomic treatments. Planta Med, 75, 178–183.
- Zhai, Z., Liu, Y., Wu, L., Senchina, D. S., Wurtele, E. S., Murphy, P. A., … Cunnick, J. E. (2007). Enhancement of innate and adaptive immune functions by multiple Echinacea species. J Med Food, 10, 423–434.